Humacyte, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Laura E. Niklason
- Full Time Employees
- 218
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2525 East North Carolina Highway 54 Durham NC United States of America 27713
- IPO Date
- Dec 1, 2020
- CIK
- 0001818382
- Website
- humacyte.com
- Similar Companies
- Business
- Humacyte, Inc. (Nasdaq: HUMA) develops and manufactures universally implantable, off-the-shelf, bioengineered human tissues and organs utilizing a proprietary scalable bioengineering platform that transforms human cells into acellular tissue engineered vessels (ATEVs) and advanced constructs designed to treat injury, disease, and chronic conditions with low infection rates and regenerative potential. Core products and investigational candidates include Symvess (acellular tissue engineered vessel-tyod), FDA-approved in December 2024 for extremity vascular trauma repair; ATEVs in Phase 3 for dialysis arteriovenous access (meeting co-primary endpoints in V007 trial), peripheral artery disease, coronary artery bypass grafting, and pediatric heart disease; advanced organ systems such as BioVascular Pancreas for type 1 diabetes and lung applications; and advanced tissue constructs for urinary conduits, tracheal replacement, and esophageal replacement. The company, founded in 2004 and headquartered in Durham, North Carolina, operates primarily in the United States with a global intellectual property footprint spanning the United States, Europe, Canada, and Australia; it targets vascular surgery, trauma centers, dialysis patients, military medical facilities, and regenerative medicine markets. Recent developments encompass the FDA's completion of Symvess product batch release review enabling commercial shipments, commencement of Symvess market launch and first sales in early 2025, a $46.7 million public offering to extend cash runway, cost reductions to align with commercial and pipeline priorities including a planned supplemental BLA for dialysis in H2 2026 and IND filing for CABG, and expansion of intellectual property in September 2025 with a new U.S. patent for bioengineered esophagus alongside coverage for trachea and urinary conduits to support pipeline advancement and potential corporate partnerships.
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Humacyte Q1 Earnings Call Highlights
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
Humacyte, Inc. (HUMA) Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients Transcript
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why